Data on Adaptimmune's trial with afami-cel published in The Lancet

USA and UK-based cancer cell therapy developer Adaptimmune Therapeutics (Nasdaq: ADAP) today announced that prestigious peer reviewed journal The Lancet has published the company's pivotal Phase II data with afamitresgene autoleucel (afami-cel.

Titled "SPEARHEAD-1: a single-arm Phase II trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," the article details clinical and translational results from afami-cel's SPEARHEAD-1 trial (NCT04044768). Investors were not impressed, sending the firm’s shares down 3.7% to $1.42 in early trading.

In the SPEARHEAD-1 trial, 44 patients with advanced synovial sarcoma were treated with a single dose of afami-cel after undergoing lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Safety findings were overall consistent with those previously observed in advanced cancer patients undergoing lymphodepleting chemotherapy and cell therapy. Hematologic toxicities were the most common adverse events. Low grade cytokine release syndrome occurred in most patients and was managed with standard treatments.